A Call for More COVID-19 Vaccine Funding, and Praise for Yale's Achievements
On July 24, United States Senator Richard Blumenthal (D-CT) highlighted research conducted at Yale School of Medicine and urged his Senate colleagues to approve more federal funding for development and distribution of vaccines to halt the COVID-19 pandemic.
Yale, Baylor Create Detailed Atlas of Cellular Change in Lungs with Fibrosis
The new research provides insight into the lungs’ cellular landscape, shows how IPF affects lung cells, and suggests both a possible explanation for patients’ breathing difficulties and potential new avenues for treatment.Source: YaleNews
New Imaging Tool Helps Researchers See Extent of Alzheimer’s Early Damage
New imaging technology allows scientists to see the widespread loss of brain synapses in early stages of Alzheimer’s disease, a finding that one day may aid in drug development, according to a new Yale University study.Source: Yale News
Caroline Johnson Receives American Cancer Society Research Scholar Grant
Caroline Johnson, Ph.D., Assistant Professor of Epidemiology in the Department of Environmental Health Sciences at Yale School of Public Health and a member of Yale Cancer Center’s Cancer Microbiology Research Program, has received a four-year, $792,000 Research Scholar Grant from the American Cancer Society (ACS).
Researchers at Yale Pursuing COVID-19 Vaccine Based on Powerful Yale Platform
Yale pathologist John “Jack” Rose believes a proven vaccine platform he pioneered decades ago using a livestock virus called vesicular stomatitis virus (VSV) could produce better immunity than other vaccine candidates, and be scaled up quickly to meet global demand.Source: YaleNews
Battling COVID-19 with robots and a library of chemicals
The Yale Center for Molecular Discovery is home to collections of 300,000 small molecules and 18,000 genomic probes. Researchers are using these collections to look for existing drugs that could be repurposed to treat people with the novel coronavirus.Source: YaleNews
Researchers devise new model to track COVID-19’s spread
Yale University researchers and colleagues in Hong Kong and China have developed an approach for rapidly tracking population flows that could help policymakers worldwide more effectively assess risk of disease spread and allocate limited resources as they combat the COVID-19 pandemic.Source: YaleNews
Yale Launches Clinical Trial for Drug to Treat Severe COVID-19 Patients
Yale researchers will begin a clinical trial at Yale-New Haven Hospital to test the effectiveness of a drug called ibudilast (MN-166) for treating acute respiratory distress syndrome (ARDS), a life-threatening lung condition developed by some of the most seriously ill COVID-19 patients.Source: YaleNews
Yale Cancer Center Study Points to Obesity as a Driver of Pancreatic Cancer
A new study led by Yale Cancer Center (YCC) researchers has demonstrated in mice that hormones released from the pancreas itself can advance the cancer—and that weight loss can stop this process in its early stages. The research was published today in the journal Cell.
Major Gift Will Support an Innovative Brain Research Collaboration
The Swiss-based NOMIS Foundation is making a large five-year award for research into what makes the human brain unique. The research will be a collaboration between the laboratories of James P. Noonan, PhD, associate professor of genetics and of neuroscience at Yale School of Medicine, and Franck Polleux, PhD, professor of neuroscience at Columbia University and a member of that school’s Zuckerman Institute. Their combined mission is to understand the brain and mind.
Gift by Rothberg Family Reinforces Yale Coronavirus Response
“Our doctors, nurses, and first responders, and all of our health care workers are saving the lives of people we love. We each need to do everything we can to keep them safe and let them know that we are there for them,” says Jonathan Rothberg.
Yale Cancer Center Reports First Test Using Immunotherapy Drug to Treat Advanced Lung Cancer Shows Benefit — And Future Promise
Researchers at Yale Cancer Center (YCC) have found that use of the checkpoint inhibitor pembrolizumab can extend life with very few side effects in this patient population.